DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.message sent
email sent successfully
You are receiving this because you have an account on www.oneGRAVESvoice.com | ||
To unsubscribe from these emails, click here |
Trusted Resources: News & Meetings
Latest announcements and gatherings
A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease
Prior clinical trials of TEPEZZA(TM) have enrolled patients with a new diagnosis of thyroid eye disease. This one is recruiting patients who have been diagnosed for at least three years – but less than eight – to assess the effectiveness on inactive/chronic TED.
https://clinicaltrials.gov/ct2/show/NCT04583735


Related Content
-
Evidence & EducationTeprotumumab for the Treatment of Active Thyroid Eye DiseaseBackground: Thyroid eye disease is a de...
-
News & MeetingsTEPEZZA Has Resumed Production – FAQHorizon Therapeutics, the developer of T...
-
News & MeetingsMeeting of Dermatologic and Ophthalmic Drugs Advisory Committee AnnouncementThe committee will discuss biologics lic...
-
Evidence & EducationComparison of treatment cost and quality-of-life impact of thyroid eye disease therapiesPurpose : Teprotumumab was approved as...
-
News & MeetingsBreakthrough Treatment for Thyroid Eye DiseaseFor those with severe inflammation from ...
-
News & MeetingsNew Data from Teprotumumab Phase 3 OPTIC Study Shows Significantly Reduced Double Vision and Improved Quality of Lif...Horizon Therapeutics plc today announced...
-
News & MeetingsHorizon Therapeutics plc Reports Strong Third-Quarter 2019 ResultsHorizon Therapeutics plc today announced...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.